|28th September 2020||Stephen Connelly||25,000||Open or private sale||$5.62||$140,395.00|
|13th July 2020||Stephen Connelly||250,000||Open or private sale||$8.13||$2,033,475.00|
|10th June 2020||Christine Zedelmayer||9,570||Other acquisition or disposition||$2.41||$23,063.70|
|10th June 2020||Jason A Keyes||5,014||Other acquisition or disposition||$2.41||$12,083.74|
|18th February 2020||Jason A Keyes||5,000||Open or private sale||$5.03||$25,137.50|
|21st January 2020||Jason A Keyes||5,000||Open or private sale||$4.41||$22,043.00|
|3rd September 2019||Jason A Keyes||5,000||Open or private sale||$3.60||$17,980.50|
|1st August 2019||Jason A Keyes||5,000||Open or private sale||$3.99||$19,941.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.